Metin Cetiner, Carsten Bergmann, Markus Bettendorf, Johanna Faust, Anja Gäckler, Bernarda Gillissen, Matthias Hansen, Maximilian Kerber, Günter Klaus, Jens König, Laura Kühlewein, Jun Oh, Annette Richter-Unruh, Julia von Schnurbein, Martin Wabitsch, Susann Weihrauch-Blüher, Lars Pape
{"title":"[Improved Care and Treatment Options for Patients with Hyperphagia-Associated Obesity in Bardet-Biedl Syndrome].","authors":"Metin Cetiner, Carsten Bergmann, Markus Bettendorf, Johanna Faust, Anja Gäckler, Bernarda Gillissen, Matthias Hansen, Maximilian Kerber, Günter Klaus, Jens König, Laura Kühlewein, Jun Oh, Annette Richter-Unruh, Julia von Schnurbein, Martin Wabitsch, Susann Weihrauch-Blüher, Lars Pape","doi":"10.1055/a-2251-5382","DOIUrl":null,"url":null,"abstract":"<p><p>Bardet-Biedl syndrome (BBS) is a rare, autosomal recessive multisystem disease. The pathophysiological origin is a dysfunction of the primary cilium. Clinical symptoms are heterogeneous and variable: retinal dystrophy, obesity, polydactyly, kidney abnormalities, hypogenitalism and developmental delays are the most common features. By the approval of the melanocortin 4 receptor agonist setmelanotide, a drug therapy for BBS-associated hyperphagia and obesity can be offered for the first time. Hyperphagia and severe obesity represent a considerable burden and are associated with comorbidity and increased mortality risk. Due to the limited experience with setmelanotide in BBS, a viable comprehensive therapy concept is to be presented. Therapy decision and management should be conducted in expert centers. For best therapeutic effects with setmelanotide adequate information of the patient about the modalities of the therapy (daily subcutaneous injection) and possible adverse drug events are necessary. Furthermore, the involvement of psychologists, nutritionists and nursing services (support for the application) should be considered together with the patient. The assessment of therapy response should be carried out with suitable outcome measurements and centrally reported to an adequate register.</p>","PeriodicalId":17846,"journal":{"name":"Klinische Padiatrie","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11383622/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinische Padiatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2251-5382","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Bardet-Biedl syndrome (BBS) is a rare, autosomal recessive multisystem disease. The pathophysiological origin is a dysfunction of the primary cilium. Clinical symptoms are heterogeneous and variable: retinal dystrophy, obesity, polydactyly, kidney abnormalities, hypogenitalism and developmental delays are the most common features. By the approval of the melanocortin 4 receptor agonist setmelanotide, a drug therapy for BBS-associated hyperphagia and obesity can be offered for the first time. Hyperphagia and severe obesity represent a considerable burden and are associated with comorbidity and increased mortality risk. Due to the limited experience with setmelanotide in BBS, a viable comprehensive therapy concept is to be presented. Therapy decision and management should be conducted in expert centers. For best therapeutic effects with setmelanotide adequate information of the patient about the modalities of the therapy (daily subcutaneous injection) and possible adverse drug events are necessary. Furthermore, the involvement of psychologists, nutritionists and nursing services (support for the application) should be considered together with the patient. The assessment of therapy response should be carried out with suitable outcome measurements and centrally reported to an adequate register.
期刊介绍:
Das Forum für wissenschaftliche Information in der Kinderheilkunde
ausgewählte Originalarbeiten aus allen Bereichen der Pädiatrie
Visite: Ihr Forum für interessante Krankengeschichten und außergewöhnliche Kasuistiken
aktuelle Fortschritte in Diagnostik und Therapie
jährliche Schwerpunkthefte: Ergebnisse der pädiatrischen Onkologie
plus Medizin und Markt
topaktuelle Informationen aus der Industrie